Composite tissue allotransplantation: a review of relevant immunological issues for plastic surgeons

Journal of Plastic, Reconstructive and Aesthetic Surgery

Volumn 61, Issue 5, 2008, Pages 481-492

  Whitaker, Iain S ^a,b   Duggan, Eileen M ^a   Alloway, Rita R ^c   Brown, Charlie ^a   McGuire, Sean ^a   Woodle, E Steve ^d   Hsiao, Eugene C ^a   Maldonado, Claudio ^a   Banis Jr , Joseph C ^a   Barker, John H ^a  

^a University of Louisville School of Medicine   (United States)

^b MORRISTON HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Composite tissue allotransplantation; Ethics; Face transplant; Hand transplant; Immunosuppression

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CORTICOSTEROID; CORTISONE; CYCLOSPORIN A; DACLIZUMAB; HYDROCORTISONE; MERCAPTOPURINE; MONOCLONAL ANTIBODY CD3; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ALLOTRANSPLANTATION; ANAPHYLAXIS; ATOPIC DERMATITIS; BACTERIAL INFECTION; BONE MARROW TOXICITY; DRUG MEGADOSE; EMBASE; GASTROINTESTINAL TOXICITY; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNE RESPONSE; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFECTION; KIDNEY TRANSPLANTATION; LIVER TOXICITY; LUNG EDEMA; LYMPHOPROLIFERATIVE DISEASE; MAINTENANCE THERAPY; MALIGNANT NEOPLASTIC DISEASE; MEDICAL RESEARCH; MEDLINE; MYCOSIS; NEPHROTOXICITY; NONHUMAN; OSTEOPOROSIS; PLASTIC SURGERY; PRIORITY JOURNAL; PROTEINURIA; PSORIASIS; PYODERMA GANGRENOSUM; REVIEW; RISK ASSESSMENT; SERUM SICKNESS; SURVIVAL RATE; TREMOR; VIRUS INFECTION;

FACIAL TRANSPLANTATION; GRAFT REJECTION; HAND; HUMANS; IMMUNOSUPPRESSION; RECONSTRUCTIVE SURGICAL PROCEDURES; TERMINOLOGY AS TOPIC; TISSUE TRANSPLANTATION; TRANSPLANTATION IMMUNOLOGY;

EID: 43049177972     PISSN: 17486815     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bjps.2007.11.019     Document Type: Review

References (106)

1. Kanitakis J., Petruzzo P., Jullien D., et al. Pathological score for the evaluation of allograft rejection in human hand (composite tissue) allotransplantation. Eur J Dermatol 15 (2005) 235-238
2. Lanzetta M., Petruzzo P., Margreiter R., et al. The International Registry on Hand and Composite Tissue Transplantation. Transplantation 79 (2005) 1210-1214
3. Jiang H.Q., Wang Y., Hu X.B., et al. Composite tissue allograft transplantation of cephalocervical skin flap and two ears. Plast Reconstr Surg 115 (2005) 31e-35e [discussion 36e-37e]
4. Devauchelle B., Badet L., Lengelé B., et al. First human face allograft: early report. Lancet (2006) 1-7
5. The first facial transplant. Lancet 366 (2005) 1984
6. Butler P.E., Hettiaratchy S., and Clarke A. Facial transplantation: a new gold standard in facial reconstruction?. J Plast Reconstr Aesthet Surg 59 (2006) 211-212
7. Man gets world's third partial face transplant. French doctors give 27-year-old with disfiguring disease a new nose, chin. [accessed January 23, 2007]. Available from:. http://www.msnbc.msn.com/id/16767785/
8. Denton M.D., Magee C.C., and Sayegh M.H. Immunosuppressive strategies in transplantation. Lancet 353 (1999) 1083-1091
9. Wigmore S.J. Face transplantation: the view from Birmingham, England. South Med J 99 (2006) 424-426
10. Converse J., and Casson P. The historical background of transplantation. In: Rapaport F.T., and Dausset J. (Eds). Human transplantation (1968), Grun & Stratton, New York
11. Da Varagine, J. Leggenda Aurea. 1952.
12. Bunger C. Gelungener versuch einer nasenbildung aus einem vollig getrennten hautstuck aus dem beine. J Chir Augenheilk 4 (1823) 569
13. Carrel A. Landmark article, Nov 14, 1908: results of the transplantation of blood vessels, organs and limbs. By Alexis Carrel. JAMA 250 (1983) 944-953
14. Carrel A. The preservation of tissues and its applications in surgery. 1912. Clin Orthop Relat Res 278 (1992) 2-8
15. Toledo-Pereyra L.H. Classics of modern surgery: the unknown man of Alexis Carrel - father of transplantation. J Invest Surg 16 (2003) 243-246
16. Guthrie C. Applications of blood vessels surgery. Blood vessel surgery of blood vessels surgery (1912), Longman Green, New York
17. Gibson T., and Medawar P.B. The fate of skin homografts in man. J Anat 77 (1943) 299-310
18. Murray J., Merrill J., and Harrison J. Renal homotransplantation in identical twins. Surg Forum 6 (1955) 432
19. Doi K. Homotransplantation of limbs in rats. A preliminary report on an experimental study with nonspecific immunosuppressive drugs. Plast Reconstr Surg 64 (1979) 613-621
20. Goldberg V.M., Porter B.B., and Lance E.M. Transplantation of the canine knee joint on a vascular pedicle. A preliminary study. J Bone Joint Surg Am 62 (1980) 414-424
21. Goldwyn R.M., Beach P.M., Feldman D., et al. Canine limb homotransplantation. Plast Reconstr Surg 37 (1966) 184-195
22. Lance E.M., Inglis A.E., Figarola F., et al. Transplantation of the canine hind limb. Surgical technique and methods of immunosuppression for allotransplantation. A preliminary report. J Bone Joint Surg Am 53 (1971) 1137-1149
23. Anon. Hand transplanted from cadaver is reamputated. Med Trib Med News 5 (1964) 23
24. Gilbert R. Transplant is successful with a cadaver forearm. Med Trib Med News 5 (1964) 20
25. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 309 (1983) 809-815
26. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. Analysis at three years. The Canadian Multicentre Transplant Study Group. N Engl J Med 314 (1986) 1219-1225
27. Danovitch G.M. Choice of immunosuppressive drugs and individualization of immunosuppressive therapy for kidney transplant patients. Transplant Proc 31 (1999) 2S-6S
28. Calne R.Y., Rolles K., White D.J., et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet 2 (1979) 1033-1036
29. Morris P.J. Cyclosporin A. Transplantation 32 (1981) 349-354
30. Press B.H., Sibley R.K., and Shons A.R. Limb allotransplantation in the rat: extended survival and return of nerve function with continuous cyclosporin/prednisone immunosuppression. Ann Plast Surg 16 (1986) 313-321
31. Daniel R.K., Egerszegi E.P., Samulack D.D., et al. Tissue transplants in primates for upper extremity reconstruction: a preliminary report. J Hand Surg [Am] 11 (1986) 1-8
32. Hovius S.E., Stevens H.P., van Nierop P.W., et al. Allogeneic transplantation of the radial side of the hand in the rhesus monkey: I. Technical aspects. Plast Reconstr Surg 89 (1992) 700-709
33. Stark G.B., Swartz W.M., Narayanan K., et al. Hand transplantation in baboons. Transplant Proc 19 (1987) 3968-3971
34. Bain J.R. Peripheral nerve and neuromuscular allotransplantation: current status. Microsurgery 20 (2000) 384-388
35. Mackinnon S.E., and Hudson A.R. Clinical application of peripheral nerve transplantation. Plast Reconstr Surg 90 (1992) 695-699
36. Mackinnon S.E., Doolabh V.B., Novak C.B., et al. Clinical outcome following nerve allograft transplantation. Plast Reconstr Surg 107 (2001) 1419-1429
37. Guimberteau J.C., Baudet J., Panconi B., et al. Human allotransplant of a digital flexion system vascularized on the ulnar pedicle: a preliminary report and 1-year follow-up of two cases. Plast Reconstr Surg 89 (1992) 1135-1147
38. Jones T.R., Humphrey P.A., and Brennan D.C. Transplantation of vascularized allogeneic skeletal muscle for scalp reconstruction in renal transplant patient. Transplant Proc 30 (1998) 2746-2753
39. Hofmann G.O., and Kirschner M.H. Clinical experience in allogeneic vascularized bone and joint allografting. Microsurgery 20 (2000) 375-383
40. Strome M., Stein J., Esclamado R., et al. Laryngeal transplantation and 40-month follow-up. N Engl J Med 344 (2001) 1676-1679
41. Levi D.M., Tzakis A.G., Kato T., et al. Transplantation of the abdominal wall. Lancet 361 (2003) 2173-2176
42. Fageeh W., Raffa H., Jabbad H., et al. Transplantation of the human uterus. Int J Gynaecol Obstet 76 (2002) 245-251
43. Shirbacheh M.V., Jones J.W., Breidenbach W.C., et al. The case for local immunosuppression in composite tissue allotransplantation. Transplant Proc 30 (1998) 2739-2742
44. Shirbacheh M.V., Ren X., Jones J.W., et al. Pharmacokinetic advantage of intra-arterial cyclosporin A delivery to vascularly isolated rabbit forelimb. I. Model development. J Pharmacol Exp Ther 289 (1999) 1185-1190
45. Shirbacheh M.V., Jones J.W., Harralson T.A., et al. Pharmacokinetics of intra-arterial delivery of tacrolimus to vascularly isolated rabbit forelimb. J Pharmacol Exp Ther 289 (1999) 1196-1201
46. Shirbacheh M.V., Harralson T.A., Jones J.W., et al. Pharmacokinetic advantage of intra-arterial cyclosporin A delivery to vascularly isolated rabbit forelimb. II. Dose dependence. J Pharmacol Exp Ther 289 (1999) 1191-1195
47. Gruber S.A., Shirbacheh M.V., Jones J.W., et al. Local drug delivery to composite tissue allografts. Microsurgery 20 (2000) 407-411
48. Lubbe A.S., Bergemann C., Riess H., et al. Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res 56 (1996) 4686-4693
49. Lubbe A.S., Bergemann C., Huhnt W., et al. Preclinical experiences with magnetic drug targeting: tolerance and efficacy. Cancer Res 56 (1996) 4694-4701
50. Prabhune K.A., Gorantla V.S., Maldonado C., et al. Mixed allogeneic chimerism and tolerance to composite tissue allografts. Microsurgery 20 (2000) 441-447
51. Gorantla V., Perez-Abadia G., Prabhune K., et al. Composite tissue allograft (CTA): tolerance induction without graft vs host disease (GvHD). Surg Forum 51 (2000) 578-579
52. Gorantla V.S., Prabhune K.A., Perez-Abadia G., et al. Composite tissue allotransplantation in chimeric hosts: part I. Prevention of graft-versus-host disease. Transplantation 75 (2003) 922-932
53. Prabhune K.A., Gorantla V.S., Perez-Abadia G., et al. Composite tissue allotransplantation in chimeric hosts part II. A clinically relevant protocol to induce tolerance in a rat model. Transplantation 76 (2003) 1548-1555
54. Perez-Abadia G., Laurentin-Perez L., Gorantla V.S., et al. Low-dose immunosuppression in a rat hind-limb transplantation model. Transpl Int 16 (2003) 835-842
55. Brouha P., Perez-Abadia G., Francois C., et al. Lymphadenctomy prior to rat hind limb allotransplantation prevents graft-versus-host disease in chimeric hosts. Transpl Int 17 (2004) 341-350
56. Francois C.G., Brouha P.C., Laurentin-Perez L.A., et al. Vascularized lymph node transplantation induces graft-versus-host disease in chimeric hosts. Transplantation 81 (2006) 1435-1441
57. Ren X., Shirbacheh M., Ustuner E., et al. Radial forelimb osteomyocutaneous flap as a pre-clinical composite tissue allograft (CTA) model in swine. Microsurgery 20 (2000) 143-149
58. Ustuner E.T., Majzoub R.K., Ren X., et al. Swine composite tissue allotransplant model for preclinical hand transplant studies. Microsurgery 20 (2000) 400-406
59. Shirbacheh M., Jones J., Breidenbach W., et al. The feasibility of human hand transplantation. Seventh IFSSH Congress (May 24-28, 1998), Vancouver, BC
60. Jones Jr. J.W., Ustuner E.T., Zdichavsky M., et al. Long-term survival of an extremity composite tissue allograft with FK506-mycophenolate mofetil therapy. Surgery 126 (1999) 384-388
61. Dubernard J.M., Owen E., Herzberg G., et al. Human hand allograft: report on first 6 months. Lancet 353 (1999) 1315-1320
62. Jones J.W., Gruber S.A., Barker J.H., et al. Successful hand transplantation. One-year follow-up. Louisville Hand Transplant Team. N Engl J Med 343 (2000) 468-473
63. Francois C.G., Breidenbach W.C., Maldonado C., et al. Hand transplantation: comparisons and observations of the first four clinical cases. Microsurgery 20 (2000) 360-371
64. Kanitakis J., Jullien D., Petruzzo P., et al. Clinicopathologic features of graft rejection of the first human hand allograft. Transplantation 76 (2003) 688-693
65. China's 1st face transplant successful. [accessed April 15, 2006]. Available from: (2006). http://news.xinhuanet.com/english/2006-04/14/content_4425653.htm
66. Gorantla V.S., Barker J.H., Jones Jr. J.W., et al. Immunosuppressive agents in transplantation: mechanisms of action and current anti-rejection strategies. Microsurgery 20 (2000) 420-429
67. Prigozhina T., and Slavin S. Transplantation of hematopoietic stem cells for induction of unresponsiveness to organ allografts. Springer Semin Immunopathol 26 (2004) 169-185
68. Monaco A.P., Clark A.W., Wood M.L., et al. Possible active enhancement of a human cadaver renal allograft with antilymphocyte serum (ALS) and donor bone marrow: case report of an initial attempt. Surgery 79 (1976) 384-392
69. Kanitakis J., Badet L., Petruzzo P., et al. Clinicopathologic monitoring of the skin and oral mucosa of the first human face allograft: Report on the first eight months. Transplantation 82 (2006) 1610-1615
70. Barry J.M. Immunosuppressive drugs in renal transplantation. A review of the regimens. Drugs 44 (1992) 554-566
71. Pirsch J.D., Miller J., Deierhoi M.H., et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 63 (1997) 977-983
72. Goto T., Kino T., Hatanaka H., et al. Discovery of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant Proc 19 (1987) 4-8
73. Ghasemian S.R., Light J.A., Currier C., et al. Tacrolimus vs Neoral in renal and renal/pancreas transplantation. Clin Transplant 13 (1999) 123-125
74. Gold B.G., Yew J.Y., and Zeleny-Pooley M. The immunosuppressant FK506 increases GAP-43 mRNA levels in axotomized sensory neurons. Neurosci Lett 241 (1998) 25-28
75. Cottrell B.L., Perez-Abadia G., Onifer S.M., et al. Neuroregeneration in composite tissue allografts: effect of low-dose FK506 and mycophenolate mofetil immunotherapy. Plast Reconstr Surg 118 (2006) 615-623 [discussion 624-615]
76. Gold B.G. FK506 and the role of immunophilins in nerve regeneration. Mol Neurobiol 15 (1997) 285-306
77. Aoyama H., Tabata N., Tanaka M., et al. Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment. Br J Dermatol 133 (1995) 494-496
78. Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. The European FK 506 Multicentre Psoriasis Study Group. Arch Dermatol 132 (1996) 419-423
79. Remitz A., Reitamo S., Erkko P., et al. Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol 141 (1999) 103-107
80. Abu-Elmagd K., Van Thiel D.H., Jegasothy B.V., et al. Resolution of severe pyoderma gangrenosum in a patient with streaking leukocyte factor disease after treatment with tacrolimus (FK 506). Ann Intern Med 119 (1993) 595-598
81. Sollinger H.W. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 60 (1995) 225-232
82. Johnson C., Ahsan N., Gonwa T., et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 69 (2000) 834-841
83. Ahsan N., Johnson C., Gonwa T., et al. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years. Transplantation 72 (2001) 245-250
84. Mendez R., Gonwa T., Yang H.C., et al. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. Transplantation 80 (2005) 303-309
85. Murray J., Lang S., Miller B., et al. Prolonged functional survival of renal autografts in the dog. Surg Gynecol Obstet 103 (1956) 15
86. Huxtable R., and Woodley J. Gaining face or losing face? Framing the debate on face transplants. Bioethics 19 (2005) 505-522
87. Ciancio G., Burke G.W., Suzart K., et al. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. Transplantation 73 (2002) 1100-1106
88. Ciancio G., Burke G.W., Gaynor J.J., et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation 77 (2004) 252-258
89. Vanrenterghem Y., van Hooff J.P., Squifflet J.P., et al. Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial. Am J Transplant 5 (2005) 87-95
90. Rostaing L., Cantarovich D., Mourad G., et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 79 (2005) 807-814
91. Ciancio G., Burke G.W., Gaynor J.J., et al. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 80 (2005) 457-465
92. Ciancio G., Burke G.W., Suzart K., et al. Efficacy and safety of daclizumab induction for primary kidney transplant recipients in combination with tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression. Transplant Proc 35 (2003) 873-874
93. Lanzetta M., Ayrout C., Gal A., et al. Experimental limb transplantation, part II: excellent return of function and indefinite survival after withdrawal of immunosuppression. Transplant Proc 36 (2004) 675-679
94. Lee W.P., Yaremchuk M.J., Pan Y.C., et al. Relative antigenicity of components of a vascularized limb allograft. Plast Reconstr Surg 87 (1991) 401-411
95. Matas A.J., Humar A., Payne W.D., et al. Decreased acute rejection in kidney transplant recipients is associated with decreased chronic rejection. Ann Surg 230 (1999) 493-498 [discussion 498-500]
96. Tufveson G., and Johnsson C. Chronic allograft dysfunction-chronic rejection revisited. Transplantation 70 (2000) 411-412
97. Kasiske B.L., Chakkera H.A., and Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 11 (2000) 1735-1743
98. Diamant S., and Shafrir E. Modulation of the activity of insulin-dependent enzymes of lipogenesis by glucocorticoids. Eur J Biochem 53 (1975) 541-546
99. Radermacher J., Meiners M., Bramlage C., et al. Pronounced renal vasoconstriction and systemic hypertension in renal transplant patients treated with cyclosporin A versus FK 506. Transpl Int 11 (1998) 3-10
100. Duijnhoven E.M., Boots J.M., Christiaans M.H., et al. Influence of tacrolimus on glucose metabolism before and after renal transplantation: a prospective study. J Am Soc Nephrol 12 (2001) 583-588
101. Barker J.H., Furr A., Cunningham M., et al. Investigation of risk acceptance in facial transplantation. Plast Reconstr Surg 118 (2006) 663-670
102. Demir Y., Ozmen S., Klimczak A., et al. Tolerance induction in composite facial allograft transplantation in the rat model. Plast Reconstr Surg 114 (2004) 1790-1801
103. Hettiaratchy S., and Butler P.E. Tolerance induction in composite facial allograft transplantation in the rat model. Plast Reconstr Surg 117 (2006) 1043-1044 [author reply 1044-1045]
104. Wekerle T., and Sykes M. Mixed chimerism and transplantation tolerance. Annu Rev Med 52 (2001) 353-370
105. Wood K.J. Transplantation tolerance. Curr Opin Immunol 3 (1991) 710-714
106. Renshaw A., Clarke A., Diver A.J., et al. Informed consent for facial transplantation. Transpl Int 19 (2006) 861-867